{"created":"2015-03-02T21:00:12+00:00","modified":"2015-05-14T15:55:47+00:00","valid":{"from":"2015-03-02T15:33:49+00:00","to":"3015-03-02T15:33:49+00:00"},"hreflang":"en","byline":"Dan Weissmann","contenttemplated":"[{\"type\":\"text/html\",\"content\":\"<p dir=\\\"ltr\\\"><span>Some patients with dementia can behave in ways that caregivers find difficult: They hit, they yell. Sometimes, they get prescribed anti-psychotics.</span></p>\"},{\"type\":\"text/html\",\"content\":\"<p dir=\\\"ltr\\\">The Food and Drug Administration says that such off-label uses are risky — <a href=\\\"http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm053171.htm\\\" target=\\\"_blank\\\">people taking them are more likely to die</a>. <span> </span>A new <a href=\\\"http://www.gao.gov/products/GAO-15-211\\\" target=\\\"_blank\\\">report from the Government Accountability Office</a> recommends steps for reducing their use.</p>\"},{\"content\":\"<p dir=\\\"ltr\\\"><span>Marketing efforts for these non-approved uses have drawn fire from federal prosecutors. In 2013, </span><a href=\\\"http://www.justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations\\\" target=\\\"_blank\\\">Johnson &amp; Johnson paid more than a billion dollars in federal fines</a><span> for improperly marketing its anti-psychotic drug Risperdal. In March of this year, a Chicago psychiatrist </span><a href=\\\"http://www.justice.gov/opa/pr/illinois-physician-pleads-guilty-taking-kickbacks-pharmaceutical-company-and-agrees-pay-379\\\" target=\\\"_blank\\\">pleaded guilty to accepting $600,000 in kickbacks</a><span> from another drug-maker.</span></p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p dir=\\\"ltr\\\"><span>Not all adoption is illicit, <span>says Dan Mendolson, CEO of</span><a href=\\\"http://avalere.com/about-us/\\\" target=\\\"_blank\\\"> Avalere, a health-care consultancy</a><span>.</span></span></p>\"},{\"content\":\"<p dir=\\\"ltr\\\"><span>&quot;A lot of the demand is driven by the patients&apos; families,&quot; he says. &quot;These are effective drugs, and the reason why they’re so widely prescribed is because they work beautifully.&quot;</span></p>\",\"type\":\"text/html\"},{\"content\":\"<span>However, they may eclipse other, safer alternatives, says <a href=\\\"http://www.jhsph.edu/faculty/directory/profile/5284/Alexander/Gcaleb/\\\" target=\\\"_blank\\\">Caleb Alexander, co-director of the Center for Drug Safety and Effectiveness</a><span> at Johns Hopkins University.</span></span>\",\"type\":\"text/html\"},{\"content\":\"<p><span>&quot;There are certainly some settings where clinicians and patients and family members are between a rock and a hard place,&quot; Alexander says.</span><span> &quot;But I don’t think it’s fair to say that there aren’t other options. And I don’t think it’s fair to say that patients are breaking down the doors, trying to access these therapies.&quot;</span></p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>The Department of Health and Human Services has been attempting to <a href=\\\"http://oig.hhs.gov/oei/reports/oei-07-08-00150.pdf\\\" target=\\\"_blank\\\">reduce the use of these drugs in nursing homes</a>. Today’s report looks at their use with patients in other settings.</p>\"}]","itags":["Marketplace Morning Report for Monday, March 2, 2015","550fa9658025976c0f40bace6c91eb01","Marketplace","Marketplace Morning Report","PMP:Marketplace_PMP"],"contentencoded":"<div class=\"barn-cleaned\"><p dir=\"ltr\"><span>Some patients with dementia can behave in ways that caregivers find difficult: They hit, they yell. Sometimes, they get prescribed anti-psychotics.</span></p>\n<p dir=\"ltr\">The Food and Drug Administration says that such off-label uses are risky — <a href=\"http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm053171.htm\" target=\"_blank\">people taking them are more likely to die</a>. <span>&nbsp;</span>A new <a href=\"http://www.gao.gov/products/GAO-15-211\" target=\"_blank\">report from the Government Accountability Office</a> recommends steps for reducing their use.</p>\n<p dir=\"ltr\"><span>Marketing efforts for these non-approved uses have drawn fire from federal prosecutors. In 2013,&nbsp;</span><a href=\"http://www.justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations\" target=\"_blank\">Johnson &amp; Johnson paid more than a billion dollars in federal fines</a><span>&nbsp;for improperly marketing its anti-psychotic drug Risperdal. In March of this year, a Chicago psychiatrist&nbsp;</span><a href=\"http://www.justice.gov/opa/pr/illinois-physician-pleads-guilty-taking-kickbacks-pharmaceutical-company-and-agrees-pay-379\" target=\"_blank\">pleaded guilty to accepting $600,000 in kickbacks</a><span>&nbsp;from another drug-maker.</span></p>\n<p dir=\"ltr\"><span>Not all adoption is illicit, <span>says Dan Mendolson, CEO of</span><a href=\"http://avalere.com/about-us/\" target=\"_blank\">&nbsp;Avalere, a health-care consultancy</a><span>.</span></span></p>\n<p dir=\"ltr\"><span>\"A lot of the demand is driven by the patients' families,\" he says.&nbsp;\"These are effective drugs, and the reason why they’re so widely prescribed is because they work beautifully.\"</span></p>\n<span>However, they may eclipse other, safer alternatives, says <a href=\"http://www.jhsph.edu/faculty/directory/profile/5284/Alexander/Gcaleb/\" target=\"_blank\">Caleb Alexander, co-director of the Center for Drug Safety and Effectiveness</a><span>&nbsp;at Johns Hopkins University.</span></span>\n<p><span>\"There are certainly some settings where clinicians and patients and family members are between a rock and a hard place,\" Alexander says.</span><span>&nbsp;\"But I don’t think it’s fair to say that there aren’t other options. And I don’t think it’s fair to say that patients are breaking down the doors, trying to access these therapies.\"</span></p>\n<p>The Department of Health and Human Services has been attempting to <a href=\"http://oig.hhs.gov/oei/reports/oei-07-08-00150.pdf\" target=\"_blank\">reduce the use of these drugs in nursing homes</a>. Today’s report looks at their use with patients in other settings.</p></div>","title":"Feds want fewer anti-psychotics prescribed to seniors","description":"Heavily marketed to treat patients with dementia, drugs can lead to death","guid":"550fa965-8025-4976-80f4-bace6c91eb01","tags":["elder care","health care","Health Care","prescription drugs","APM","dementia","Health"],"published":"2015-03-02T15:33:49+00:00","teaser":"Heavily marketed to treat patients with dementia, drugs can lead to death","audio":[{"meta":{"crop":"primary","height":"340","width":"610"},"href":"http://www.marketplace.org/sites/default/files/styles/primary-image-610x340/public/GettyImages_454966934.jpg?itok=VwAr56B6","type":"image/jpeg"},{"format":"MP3","meta":{"duration":82,"api":{"type":"application/json","href":"http://api.publicradio.org/audio/v2?ref=pmp&id=apm-audio:/marketplace/segments/2015/03/02/mp_20150302_seg_06"},"duration_hms":"00:01:22"},"type":"audio/mpeg","href":"http://play.publicradio.org/pmp/d/podcast/marketplace/segments/2015/03/02/mp_20150302_seg_06_64.mp3"}]}